ECSP066595A - ANTI-IGF-I RECEIVER ANTIBODY - Google Patents

ANTI-IGF-I RECEIVER ANTIBODY

Info

Publication number
ECSP066595A
ECSP066595A EC2006006595A ECSP066595A ECSP066595A EC SP066595 A ECSP066595 A EC SP066595A EC 2006006595 A EC2006006595 A EC 2006006595A EC SP066595 A ECSP066595 A EC SP066595A EC SP066595 A ECSP066595 A EC SP066595A
Authority
EC
Ecuador
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
EC2006006595A
Other languages
Spanish (es)
Inventor
Daniel Tavares
Rajeeva Singh
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ECSP066595A publication Critical patent/ECSP066595A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotóxicos, que específicamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-I, IGF-II y suero en el crecimiento y supervivencia de células de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjunción con otros agente terapéuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-I, tales como cáncer de pecho, cáncer de colon, cáncer de pulmón, sarcoma sinovial, cáncer de próstata, y cáncer pancreático, y los anticuerpos derivatizados se pueden utilizar en el diagnóstico y formación de imágenes de tumores que expresan niveles elevados del IGF-I.Antibodies, humanized antibodies, coated antibodies, antibody fragments, derivatized antibodies and conjugated thereof with cytotoxic agents, which specifically bind to, and inhibit the insulin-like growth factor I receptor, antagonize the effects of IGF-I , IGF-II and serum in the growth and survival of tumor cells, and which substantially lack agonist activity. The antibodies and fragments thereof can therefore be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors expressing elevated levels of the IGF-I receptor, such as breast cancer, colon cancer, lung cancer, Synovial sarcoma, prostate cancer, and pancreatic cancer, and derivatized antibodies can be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I.

EC2006006595A 2003-12-08 2006-05-31 ANTI-IGF-I RECEIVER ANTIBODY ECSP066595A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
ECSP066595A true ECSP066595A (en) 2006-10-17

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006595A ECSP066595A (en) 2003-12-08 2006-05-31 ANTI-IGF-I RECEIVER ANTIBODY

Country Status (13)

Country Link
EP (1) EP1692176A4 (en)
JP (1) JP2008502589A (en)
KR (1) KR20070001883A (en)
CN (1) CN1886424A (en)
AU (1) AU2004303792A1 (en)
BR (1) BRPI0417406A (en)
CA (1) CA2548065A1 (en)
CR (1) CR8426A (en)
EA (1) EA009807B1 (en)
EC (1) ECSP066595A (en)
IL (1) IL174770A0 (en)
MX (1) MXPA06005540A (en)
NO (1) NO20063155L (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095846A (en) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 Antibody formulations
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (en) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody
EP4678186A1 (en) * 2023-03-07 2026-01-14 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143514A0 (en) * 1998-12-04 2002-04-21 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (en) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. Uses of anti-insulin-like growth factor ⅰ receptor antibodies

Also Published As

Publication number Publication date
JP2008502589A (en) 2008-01-31
EP1692176A4 (en) 2008-11-12
AU2004303792A1 (en) 2005-07-07
EA200600931A1 (en) 2006-10-27
EP1692176A1 (en) 2006-08-23
NO20063155L (en) 2006-08-11
IL174770A0 (en) 2006-08-20
KR20070001883A (en) 2007-01-04
EA009807B1 (en) 2008-04-28
MXPA06005540A (en) 2006-08-17
CR8426A (en) 2007-12-04
CA2548065A1 (en) 2005-07-07
BRPI0417406A (en) 2007-04-03
CN1886424A (en) 2006-12-27

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
AR061911A1 (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
ES2571235T3 (en) Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
CL2017001580A1 (en) Antibody or antibody fragment against humanized antibody cd38, conjugated to the antibody with a cytotoxic compound pharmaceutical composition with said antibodies using antibodies to treat cancer or autoimmune disease method to diagnose cancer polynucleotide vector and host cell.
UA94388C2 (en) Anti-integrin immunoconjugate and treatment method using thereof
NO20070945L (en) Induction of apoptosis in tumor cells expressing Toll-like receptor
GT200600324A (en) NEW ANTI-IGF-IR ANTIBODIES AND USES OF THE SAME
AR061245A1 (en) COMPOSITIONS AND METHODS FOR VASCULAR DEVELOPMENT MODULATION
CU20130130A7 (en) ANTIBODIES TYPE RECEIVER OF SPECIFIC T-CELLS FOR A WT1 PEPTIDE PRESENTED BY HLA-A2
CO6612264A2 (en) Therapeutic proteins of the binding to dll 4
AR074360A1 (en) MONOCLONAL ANTIBODY OR FRAGMENT OF UNION TO ANTIGEN OF THE SAME PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION
DOP2013000045A (en) ANTI-OX40 ANTIBODIES AND METHODS OF THE SAME USE
CL2008003846A1 (en) Use of compounds derived from 1,2,4-triazolo fused with heterocycles, which act as ligands of the androgen receptor (ar); compounds; Preparation process; Pharmaceutical composition and the use of said compounds for the treatment of prostate cancer.
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
EA032908B1 (en) ANTIBODY MEDICINE (ADC) CONJUGATES THAT CONTACT PROTEINS 158P1D7
EA202193309A1 (en) ANTIBODY TO TISSUE FACTOR-DRUG CONJUGATES AND RELATED METHODS
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
CR8426A (en) ANTI-IGF-I RECEIVER ANTIBODY
CO6331345A2 (en) COMPOSITIONS AND METHODS THAT PROVIDE A CELLED HYBRIDOMINE LINE DEPOSITED AS NO. OF ACCESS ATCC PTA-9387 AND AN ANTIBODY PRODUCED BY THIS HYBRIDOMA CELL LINE
EA200601405A1 (en) HUMANIZED ANTIBODY
MX2024011939A (en) Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
DOP2009000003A (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
Cadden An investigation into the role of oncoproteins in neuroendocrine tumour development.